Products
XmAb™2513
Our lead XmAb™ candidate, XmAb™2513, entered clinical development in 2008 for the treatment of relapsed Hodgkin lymphoma and T cell lymphomas. XmAb™2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. XmAb™2513 has been engineered to contain an XmAb™ Fc domain to greatly increase its cytotoxic potency. XmAb™2513 shows superior activity in recruiting primary human immune cells to kill tumor cells in in vitro models and is active in blocking tumor growth in rodent models. XmAb™2513 was humanized with Xencor's XmAb Fv technology and was well-tolerated in primate models. XmAb™2513 is readily manufactured using standard monoclonal antibody production methods.
About Hodgkin Lymphoma and T cell Lymphomas
According to the U.S. National Institutes of Health, lymphomas account for about five percent of all cases of cancer in the United States. Of the nearly 500,000 Americans with lymphoma, 142,000 are cases in Hodgkin lymphoma (HL), according to the Lymphoma Research Foundation (LRF). T cell lymphomas account for approximately 15 percent of all non-Hodgkin's lymphoma (NHL) patients in the United States, according to the LRF. Both are most often treated with a chemotherapy regimen, radiation therapy or a combination of the two. HL, in particular, has a cure rate of 93%, but there is a greater concern with late adverse effects of treatment. Incidence rates with NHL have more than doubled since the 1970s, but survival rates are beginning to increase.